活血化瘀方联合甲氨蝶呤治疗类风湿关节炎的临床研究

田雨; 蒲月红; 张翔宇; 朱竹菁; 周珺; 陈晓旭; 茅建春; 苏励

doi:10.16305/j.1007-1334.2022.2208008

您当前的位置：

首页 >

文章列表页 >

活血化瘀方联合甲氨蝶呤治疗类风湿关节炎的临床研究

临床试验 | 更新时间：2022-12-22

- 活血化瘀方联合甲氨蝶呤治疗类风湿关节炎的临床研究
- Clinical study on application of Huoxue Huayu Decoction combined with methotrexate in treatment of rheumatoid arthritis
- 上海中医药杂志 2022年56卷第12期页码：68-72
- 作者机构：
  
  1.上海中医药大学附属龙华医院风湿科（上海 200032）
  2.上海中医药大学附属岳阳中西医结合医院急诊科（上海 200437）
  3.上海市第十人民医院重症医学科（上海 200072）
- 作者简介：
  
  田雨，男，博士，副主任医师，主要从事风湿病中西医诊治及名中医经验传承工作
  苏励，教授，主任医师，博士研究生导师； E-mail：suli2002@vip.sina.com
- 基金信息：
  
  上海市科委科技计划项目(18401900900)
- DOI：10.16305/j.1007-1334.2022.2208008
  中图分类号：
扫描看全文
田雨,蒲月红,张翔宇,等.活血化瘀方联合甲氨蝶呤治疗类风湿关节炎的临床研究[J].上海中医药杂志,2022,56(12):68-72.

TIAN Yu,PU Yuehong,ZHANG Xiangyu,et al.Clinical study on application of Huoxue Huayu Decoction combined with methotrexate in treatment of rheumatoid arthritis[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(12):68-72.
田雨,蒲月红,张翔宇,等.活血化瘀方联合甲氨蝶呤治疗类风湿关节炎的临床研究[J].上海中医药杂志,2022,56(12):68-72. DOI： 10.16305/j.1007-1334.2022.2208008.

TIAN Yu,PU Yuehong,ZHANG Xiangyu,et al.Clinical study on application of Huoxue Huayu Decoction combined with methotrexate in treatment of rheumatoid arthritis[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(12):68-72. DOI： 10.16305/j.1007-1334.2022.2208008.

摘要

目的,2,观察活血化瘀方联合甲氨蝶呤治疗类风湿关节炎（RA）的临床疗效。,方法,2,将80例RA患者随机分为治疗组和对照组，每组40例。两组均给予甲氨蝶呤口服治疗，治疗组加服活血化瘀方，对照组加服活血化瘀方模拟方。两组疗程均为6个月。疗程结束后，比较两组患者的中医证候疗效、中医证候积分、疾病活动度（DAS28）评分、红细胞沉降率（ESR）、C-反应蛋白（CRP）、类风湿因子（RF）、抗环瓜氨酸肽（CCP）抗体、纤维蛋白原（Fg）、血管内皮生长因子（VEGF）及关节滑膜血管翳增殖的变化情况。,结果,2,①最终完成试验者73例，治疗组37例，对照组36例。②治疗后，治疗组总有效率为89.19%，对照组总有效率为77.78%；两组中医证候疗效比较，治疗组优于对照组（,P,<,0.05）。③治疗前后组内比较，两组DAS28评分、中医证候积分均较治疗前降低（,P,<,0.05）；组间治疗后比较，两组DAS28评分差异无统计学意义（,P,>,0.05），治疗组中医证候积分比对照组明显降低（,P,<,0.05）。④治疗前后组内比较，两组RF、ESR、CRP、抗CCP抗体水平均较治疗前降低（,P,<,0.05）；组间治疗后比较，治疗组RF、CRP水平低于对照组（,P,<,0.05）。⑤治疗前后组内比较，治疗组Fg、VEGF水平均较治疗前降低（,P,<,0.05）；组间治疗后比较，治疗组Fg、VEGF水平低于对照组（,P,<,0.05）。⑥治疗前后组内比较，两组关节滑膜血管翳分级均优于治疗前（,P,<,0.05）；组间治疗后比较，治疗组关节滑膜血管翳分级优于对照组（,P,<,0.05）。,结论,2,活血化瘀方联合甲氨蝶呤治疗RA具有较好的临床疗效，能有效下调CRP、Fg、VEGF水平，具有一定的抑制关节滑膜血管翳增殖的作用。

Abstract

Objective,2,To observe the clinical effect of application of Huoxue Huayu decoction combined with methotrexate in the treatment of rheumatoid arthritis.,Methods,2,80 patients with rheumatoid arthritis were randomly divided into treatment group and control group， 40 patients in each group. Both groups were treated with methotrexate. The treatment group was added with Huoxue Huayu Decoction， while the control group was added with Huoxue Huayu Simulated Decoction. The course of treatment in both groups was 6 months. After treatment， the TCM syndrome curative effect， TCM syndromes score， disease activity（DAS28） score， erythrocyte sedimentation rate （ESR）， C-reactive protein （CRP）， rheumatoid factor （RF）， anti-cyclic citrullinated peptide （CCP）antibody， fibrinogen （Fg）， vascular endothelial growth factor （VEGF） and proliferation of synovial pannus were observed.,Results,2,①Finally， 73 patients completed the clinical trial， 37 patients in the treatment group and 36 patients in the control group. ② After treatment， the total effective rate of the treatment group was 89.19%， and that of the control group was 77.78%. Comparing the curative effect of TCM syndromes between the two groups， the treatment group was better than the control group （,P,<,0.05）. ③After treatment.， the scores of DAS28 and TCM syndromes of the two groups decreased （,P,<,0.05）. After treatment， there was no significant difference in DAS28 score between the two groups （,P,>,0.05）， and the TCM syndrome score of the treatment group was significantly lower than that of the control group （,P,<,0.05）. ④After treatment， the levels of RF， ESR， CRP and anti-CCP in both groups were lower than those before treatment （,P,<,0.05）. After treatment， the levels of RF and CRP in treatment group were lower than those in control group （,P,<,0.05）. ⑤After treatment， the levels of Fg and VEGF in the treatment group were lower than those before treatment （,P,<,0.05）， and were lower than those in the control group （,P,<,0.05）. ⑥Comparison between before and after treatment， the synovial pannus grades of both groups were better than those before treatment （,P,<, 0.05）； After treatment， the grade of synovial pannus in the treatment group was better than that in the control group （,P,<,0.05）.,Conclusion,2,The application of Huoxue Huayu decoction combined with methotrexate in the treatment of rheumatoid arthritis has a good clinical effect， it can effectively down regulate the levels of CRP， Fg and VEGF， and inhibit the proliferation of synovial pannus.

关键词

类风湿关节炎活血化瘀方甲氨蝶呤中医药疗法临床试验

Keywords

rheumatoid arthritisHuoxue Huayu Decoctionmethotrexatetraditional Chinese medicine therapyclinical trial

references

HIROHATA S， SAKAKIBARA J. Angiogenesis as a possible elusive triggering factor in rheumatoid arthritis［J］. Lancet， 1999， 353（9161）： 1331.

WALSH D A， WADE M， MAPP P I， et al. Focally regulated endothelial proliferation and cell death in human synovium［J］. Am J Pathol， 1998， 152（3）： 691-702.

SCHROEDER M， VIEZENS L， FUHRHOP I， et al. Angiogenic growth factors in rheumatoid arthritis［J］. Rheumatol Int， 2013， 33（2）： 523-527.

ARNETT F C， EEWORTHY S M， BLOCH D A， et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis［J］. Arthritis Rheum， 1988， 31（3）： 314-324.

国家药品监督管理局. 中药新药临床研究指导原则（试行）［M］.北京：中国医药科技出版社，2002： 115-119.

DM V D， VAN H M， VAN R P， et al. Development of a disease activetyscroe based on judgment in clinical practice by rheumatolongists［J］. J Rheumatol， 1991， 20（3）： 579-581.

TAKASE K，OHNO S，TAKENO M，et al．Simultaneous evaluation of long-lasting knee synovitis in patients arthroplasty by power Doppler ultrasonography and contrast-enhanced MRI in comparison with histopathology［J］. Clin Exp Rheumatol， 2012， 30（1）： 85-92.

梁先念，姚莉琴. 79例类风湿性关节炎（RA）患者血流变测定分析［J］. 中国血液流变学杂志，2003，13（1）：78-79.

曾惠琼，扶忠超，黄新民，等. D-二聚体、纤维蛋白原、转铁蛋白水平对类风湿关节炎的临床意义［J］. 检验医学，2017， 32（10）： 883-885.

JIN T， BOKEAREWA M， AMU S， et al. Impact of short-term therapies with biologics on prothrombotic biomarkers in rheumatoid arthritis［J］. Clin Exp Rheumatol， 2009， 27（3）： 491-494.

INGEGNOLI F， FANTINI F， FAVALLI E G， et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis：effects of tumornecrosis factor-alpha blockade［J］. J Autoimmun， 2008， 31（2）： 175-179.

俞烜华，黄惠娟，李扬宇. 纤维蛋白原、纤维蛋白（原）降解产物、D-二聚体与类风湿关节炎疾病活动指标的关系［J］. 中国医学创新，2019， 16（35）： 57-61.

SARANADASA M， WANG E S．Vascular endothelial growth factor inhibition： conflicting roles in tumor growth［J］. Cytokine， 2011， 53（2）： 115-129．

SZEKANECZ Z， KOCH A E．Targeting angiogenesis in rheumatoid arthritis［J］．Curr Rheumatol Rev， 2008， 4（4）： 298-303．

MALEMUD C J. Intracellular signaling pathways in rheumatoid arthritis［J］. Clin Cell Immunol， 2013， 19（4）： 160.

HUA S， DIAS T H. Hypoxia-inducible factor（hif）as a target for novel therapies in rheumatoid arthritis［J］. Front Pharmacol， 2016， 7（1）： 184.

AGNIESZKA P G， ANDRZEJ P， KATARZYNA R P， et al. Relationship between VEGF gene polymorphisms and serum VEGF protein levels in patients with rheumatoid Arthritis［J］. PLoS One， 2016， 11（8）： e0160769.

NAGASHIMA M， ASANO G， YOSHINO S. Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis［J］. J Rheumatol， 2000， 27： 2339-2342.

IKEDA M， HOSODA Y， HIROSE S， et al. Expression of vascular endothelial growth factor isoforms and their receptors flt-1， KDR， and neuropilin-1 in synovial tissues of rheumatoid arthritis［J］. J Pathol， 2000， 191（4）： 426-433.

LEE S S， JOO Y S， KIM W U， et al. Vascular endothelial grow factor levels in serum and synovial fluid of patients with rheumatoid arthritis［J］. Clin Exp Rheumatol， 2001， 19（3）： 321-324.

BALLARA S， TAYLOR P C， REUSCH P， et al. Raised serum vascular endothelial growth factors levels are associated with destructive change in inflammatory arthritis［J］. Arthritis Rheum， 2001， 44（9）： 2055-2064.

CLAVEL G， BESSIS N， LEMEITER D， et al. Angiogenesis markers（VEGF， soluble receptor of VEGF angiopoietin-1）in very early arthritis and their association with inflammation and joint destruction［J］. Clin Immunol， 2007， 124（2）： 158-164.

CHEN Y， DAWES P T， MATTEY D L. Polymorphism in the vascular endothelial growth factor A（VEGFA）gene is associated with serum VEGF-A level and disease activity in rheumatoid arthritis： differential effect of cigarette smoking［J］. Cytokine， 2012， 58（3）： 390-397.

SONE H， SAKAUCHI M， TAKAHASHI A， et al. Elevated levels of vascular endothelial growth factor in the sero of patients with rheumatoid arthritis correlation with disease activity［J］. Life Sci， 2001， 69 （16）： 1861-1869.

浏览量

178

下载量

CSCD

CNKI被引量

文章被引用时，请邮件提醒。

提交

工具集

关联资源

基于网络药理学探讨益肾蠲痹丸治疗类风湿关节炎的作用机制

苏励从瘀论治类风湿关节炎的经验

芪龙祛瘀合剂加味方联合外治调护治疗气虚血瘀型下肢静脉性溃疡的临床研究

扶正和解方干预新型冠状病毒奥密克戎变异株无症状感染儿童的临床研究

基于“心痹”理论论治类风湿关节炎的心血管损伤